Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018141730) NEURONAL CELL PROTECTIVE EFFECT OF ANTIBODIES SPECIFIC FOR THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/141730 International Application No.: PCT/EP2018/052239
Publication Date: 09.08.2018 International Filing Date: 30.01.2018
IPC:
A61K 39/00 (2006.01) ,C07K 16/18 (2006.01) ,A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
SANOFI [FR/FR]; 54, rue La Boétie 75008 PARIS, FR
Inventors:
TAUPIN, Véronique; FR
DEDIEU, Jean-François; FR
COHEN, Caroline; FR
BERTRAND, Philippe; FR
Agent:
BLOT, Philippe; FR
HABASQUE, Etienne; FR
DOMENGO, Bertrand; FR
COLOMBIE, Damien; FR
HOLTZ, Béatrice; FR
NEYRET, Daniel; FR
Priority Data:
17305110.331.01.2017EP
Title (EN) NEURONAL CELL PROTECTIVE EFFECT OF ANTIBODIES SPECIFIC FOR THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE
(FR) EFFET PROTECTEUR DE CELLULES NEURONALES D'ANTICORPS SPÉCIFIQUES POUR LA FORME PROTOFIBRILLAIRE DU PEPTIDE BÊTA-AMYLOÏDE
Abstract:
(EN) The present invention relates to an antibody specific for the protofibrillar form of the Aβ peptide for use in the prevention and/or the treatment of a neurodegenerative disease involving Aβ peptide aggregation, in particular for the prevention of Alzheimer's disease and/or the treatment of an early stage of symptomatic Alzheimer's disease. The antibody may thus be used before the appearance of memory loss and impaired cognitive functions or at the earliest stages of the disease. Said antibody has indeed a neuronal cell protective effect against Aβ peptide-induced neurotoxicity.
(FR) La présente invention concerne un anticorps spécifique pour la forme protofibrillaire du peptide Aβ destiné à être utilisé dans la prévention et/ou le traitement d'une maladie neurodégénérative impliquant l'agrégation de peptides Aβ, en particulier pour la prévention de la maladie d'Alzheimer et/ou le traitement d'un stade précoce de la maladie d'Alzheimer symptomatique. L'anticorps peut ainsi être utilisé avant l'apparition de la perte de mémoire et l'altération des fonctions cognitives ou aux stades les plus précoces de la maladie. Ledit anticorps a effectivement un effet protecteur de cellules neuronales contre la neurotoxicité induite par les peptides Aβ.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)